...
rapp-img

Rapport Therapeutics, Inc. Common Stock, Common Stock

RAPP

NMQ

$18.56

-$0.21

(-1.12%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$762.25M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
112.70K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$16.55 L
$29.74 H
$18.56

About Rapport Therapeutics, Inc. Common Stock, Common Stock

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameRAPPSectorS&P500
1-Week Return-9.6%-3.72%-0.05%
1-Month Return-12.99%-1.85%2.75%
3-Month Return-1.22%-11.4%7.4%
6-Month Return-26.87%-4.41%10.47%
1-Year Return-10.77%4.13%27.57%

Financials

Dec '22Dec '23
Total Revenue--[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue15.00K112.00K[{"date":"2022-12-31","value":13.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(15.00K)(112.00K)[{"date":"2022-12-31","value":-1500000,"profit":false},{"date":"2023-12-31","value":-11200000,"profit":false}]
Gross Margin-(Infinity%)[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses10.35M36.07M[{"date":"2022-12-31","value":28.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(10.37M)(36.18M)[{"date":"2022-12-31","value":-1036700000,"profit":false},{"date":"2023-12-31","value":-3617900000,"profit":false}]
Total Non-Operating Income/Expense-3.93M[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(10.65M)(34.78M)[{"date":"2022-12-31","value":-1065200000,"profit":false},{"date":"2023-12-31","value":-3477600000,"profit":false}]
Income Taxes-10.00K[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-(34.79M)[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3478600000,"profit":false}]
Income From Continuous Operations-(34.79M)[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3478600000,"profit":false}]
Income From Discontinued Operations--[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(10.65M)(34.79M)[{"date":"2022-12-31","value":-1065200000,"profit":false},{"date":"2023-12-31","value":-3478600000,"profit":false}]
EPS (Diluted)--[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RAPP
Cash Ratio 45.17
Current Ratio 45.91

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RAPP
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RAPP
Debt Ratio Lower is generally better. Negative is bad. 0.02
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.98

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RAPP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.26
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Rapport Therapeutics, Inc. Common Stock share price today?

Rapport Therapeutics, Inc. Common Stock (RAPP) share price today is $18.56

Can Indians buy Rapport Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Rapport Therapeutics, Inc. Common Stock (RAPP) on Vested. To buy Rapport Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RAPP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Rapport Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Rapport Therapeutics, Inc. Common Stock (RAPP) via the Vested app. You can start investing in Rapport Therapeutics, Inc. Common Stock (RAPP) with a minimum investment of $1.

How to invest in Rapport Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Rapport Therapeutics, Inc. Common Stock (RAPP) via Vested in three simple steps:

  • Click on Sign Up or Invest in RAPP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Rapport Therapeutics, Inc. Common Stock shares
What is Rapport Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Rapport Therapeutics, Inc. Common Stock (RAPP) is $29.74. The 52-week low price of Rapport Therapeutics, Inc. Common Stock (RAPP) is $16.55.

What is Rapport Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Rapport Therapeutics, Inc. Common Stock (RAPP) is

What is Rapport Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Rapport Therapeutics, Inc. Common Stock (RAPP) is 2.26

What is Rapport Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Rapport Therapeutics, Inc. Common Stock (RAPP) is 0.00%

What is the Market Cap of Rapport Therapeutics, Inc. Common Stock?

The market capitalization of Rapport Therapeutics, Inc. Common Stock (RAPP) is $762.25M

What is Rapport Therapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Rapport Therapeutics, Inc. Common Stock is RAPP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top